title: Precision medicine in oncology needs to integrate pharmacogenetic profiling.
authors.affiliation: Department of Urology, Tenon Hospital, Hôpitaux Universitaires Paris-EST, Assistance publique Hôpitaux de Paris, Paris, France; CeRePP, GRC5, ONCOTYPE-URO, UPMC University Paris 06, Paris, France. Electronic address: olivier.cussenot@tnn.aphp.fr.
authors.forename: Olivier
authors.initials: O
authors.lastname: Cussenot
authors.affiliation: CeRePP, GRC5, ONCOTYPE-URO, UPMC University Paris 06, Paris, France.
authors.forename: Geraldine
authors.initials: G
authors.lastname: Cancel-Tassin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D020641:Polymorphism, Single Nucleotide; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D051544:Cytochrome P-450 CYP3A